KR20190040030A - 암 치료용 티오히단토인 안드로겐 수용체 길항제 - Google Patents

암 치료용 티오히단토인 안드로겐 수용체 길항제 Download PDF

Info

Publication number
KR20190040030A
KR20190040030A KR1020197007833A KR20197007833A KR20190040030A KR 20190040030 A KR20190040030 A KR 20190040030A KR 1020197007833 A KR1020197007833 A KR 1020197007833A KR 20197007833 A KR20197007833 A KR 20197007833A KR 20190040030 A KR20190040030 A KR 20190040030A
Authority
KR
South Korea
Prior art keywords
oxo
thioxo
cpd
methyl
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197007833A
Other languages
English (en)
Korean (ko)
Inventor
질스 씨. 빅난
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20190040030A publication Critical patent/KR20190040030A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197007833A 2016-08-22 2017-08-22 암 치료용 티오히단토인 안드로겐 수용체 길항제 Ceased KR20190040030A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377932P 2016-08-22 2016-08-22
US62/377,932 2016-08-22
PCT/IB2017/055063 WO2018037342A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20190040030A true KR20190040030A (ko) 2019-04-16

Family

ID=60009664

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197007833A Ceased KR20190040030A (ko) 2016-08-22 2017-08-22 암 치료용 티오히단토인 안드로겐 수용체 길항제

Country Status (12)

Country Link
US (1) US20190209539A1 (enExample)
EP (1) EP3500259A1 (enExample)
JP (1) JP2019528290A (enExample)
KR (1) KR20190040030A (enExample)
CN (1) CN109640986A (enExample)
AU (1) AU2017316756A1 (enExample)
BR (1) BR112019003406A2 (enExample)
CA (1) CA3034449A1 (enExample)
MA (1) MA45992A (enExample)
MX (1) MX2019002097A (enExample)
RU (1) RU2019108092A (enExample)
WO (1) WO2018037342A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019029521A1 (zh) * 2017-08-07 2019-02-14 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
SG11202108300VA (en) 2019-02-01 2021-08-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Crystal of diarylthiohydantoin compound
CN115403624B (zh) * 2022-09-30 2024-08-27 上海应用技术大学 一种二芳基硫代乙内酰脲化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3124481B1 (en) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2911666B1 (en) * 2012-10-26 2022-08-24 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Also Published As

Publication number Publication date
AU2017316756A1 (en) 2019-02-21
BR112019003406A2 (pt) 2019-05-21
CN109640986A (zh) 2019-04-16
RU2019108092A3 (enExample) 2020-11-30
MX2019002097A (es) 2019-05-15
US20190209539A1 (en) 2019-07-11
EP3500259A1 (en) 2019-06-26
WO2018037342A1 (en) 2018-03-01
MA45992A (fr) 2019-06-26
JP2019528290A (ja) 2019-10-10
RU2019108092A (ru) 2020-09-22
CA3034449A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
US10981926B2 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
CN111989332B (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
EP4441053A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN107286077B (zh) 一种选择性的c-kit激酶抑制剂
WO2021245051A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN103501610A (zh) Pi3激酶抑制剂和其用途
US20190337924A1 (en) Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
WO2018037342A1 (en) Thiohydantoin androgen receptor antagonists for the treatment of cancer
CN110167556A (zh) 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂
EP4342895A1 (en) Heteroaryl derivative compound and use thereof
US20240016795A1 (en) Bromodomain inhibitors for androgen receptor-driven cancers
Sun et al. Discovery of a novel benzofuran-7-carboxamide-based PARP1/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance
CN114555597B (zh) 异柠檬酸脱氢酶（idh）抑制剂
WO2023024545A1 (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
EP3878841B1 (en) Indazole kinase inhibitor and use thereof
RU2789405C2 (ru) Ингибитор киназы pan-kit, имеющий структуру хинолина, и его применение

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190318

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200814

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220415

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220415

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I